header
Image from OpenLibrary

Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic rats / Hamed Saeed Mahmoud Abdallah ; Supervised Helmy Moawad Sayed , Amer Ramadan Ali Ayad , Nahla Shehata Kotb

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Hamed Saeed Mahmoud Abdallah , 2020Description: 118 P . : charts , facsmilies ; 25cmOther title:
  • التداخلات التسممية لدواء روميبلستيم وريتوكسيماب فى الجرذان الطبيعية و المصابة بنقص الصفائح الدموية المناعى [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology Summary: Pathogenesis of immune thrombocytopenia involves 2 major mechanisms: increased platelet destruction and decreased platelet production. Conventional treatments for ITP address only symptoms of increased platelet destruction. Treatment drug therapy is associated with undesirable and unpredictable side effects. Novel therapies have proved its efficacy in managing ITP with few side effects alternative to splenectomy. In this study, the experimental rats showed synergistic effect of co-administration of Romiplostim and Rituximab in normal and diseased groups. This is comparable to clinical data demonstrating that patients whose disease is refractory to conventional treatments may benefit from this combination. Romiplostim activate TPO receptors on megakaryocytes and induce platelet production via the JAK2 and STAT5 kinase pathways, and it has proven efficacious in most refractory patients with ITP. Rituximab acts an anti-CD20-directed cytolytic monoclonal antibody, works by inhibiting B cells from producing autoantibodies as well as reverting T-cell abnormalities in patients who respond to treatment. It is used off-label for the treatment of patients with ITP
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.09.M.Sc.2020.Ha.T (Browse shelf(Opens below)) Not for loan 01010110081557000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.08.09.M.Sc.2020.Ha.T (Browse shelf(Opens below)) 81557.CD Not for loan 01020110081557000

Thesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology

Pathogenesis of immune thrombocytopenia involves 2 major mechanisms: increased platelet destruction and decreased platelet production. Conventional treatments for ITP address only symptoms of increased platelet destruction. Treatment drug therapy is associated with undesirable and unpredictable side effects. Novel therapies have proved its efficacy in managing ITP with few side effects alternative to splenectomy. In this study, the experimental rats showed synergistic effect of co-administration of Romiplostim and Rituximab in normal and diseased groups. This is comparable to clinical data demonstrating that patients whose disease is refractory to conventional treatments may benefit from this combination. Romiplostim activate TPO receptors on megakaryocytes and induce platelet production via the JAK2 and STAT5 kinase pathways, and it has proven efficacious in most refractory patients with ITP. Rituximab acts an anti-CD20-directed cytolytic monoclonal antibody, works by inhibiting B cells from producing autoantibodies as well as reverting T-cell abnormalities in patients who respond to treatment. It is used off-label for the treatment of patients with ITP

Issued also as CD

There are no comments on this title.

to post a comment.